These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30006421)

  • 21. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
    Weber MM; Fottner C
    Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel biomarkers in bladder cancer.
    Cheng ML; Iyer G
    Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis.
    Choi S; Zhou M; Bahrani E; Martin BA; Ganjoo KN; Zaba LC
    Br J Haematol; 2021 Jun; 193(6):e44-e47. PubMed ID: 33954981
    [No Abstract]   [Full Text] [Related]  

  • 25. Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and the skin of immunosuppressed patients.
    Dictor M; Rambech E; Way D; Witte M; Bendsöe N
    Am J Pathol; 1996 Jun; 148(6):2009-16. PubMed ID: 8669485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
    Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D
    Science; 2018 Oct; 362(6411):. PubMed ID: 30309915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphangioma-like Kaposi sarcoma: case report.
    Posada García C; García-Cruz A; García-Doval I; De La Torre C; Cruces MJ
    Dermatol Online J; 2009 Sep; 15(9):13. PubMed ID: 19931000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmacytoid dendritic cells in skin lesions of classic Kaposi's sarcoma.
    Karouni M; Kurban M; Abbas O
    Arch Dermatol Res; 2016 Sep; 308(7):487-92. PubMed ID: 27372661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Inhibitor Therapy in Breast Cancer.
    Santa-Maria CA; Nanda R
    J Natl Compr Canc Netw; 2018 Oct; 16(10):1259-1268. PubMed ID: 30323094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma.
    Tedeschi R; Bidoli E; Bortolin MT; Schioppa O; Vaccher E; De Paoli P
    Oncotarget; 2015 Oct; 6(30):30334-42. PubMed ID: 26296972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human herpesvirus 8 investigations: a role in the clinical management of Kaposi's sarcoma?
    Simonart T; Hermans P; Van Vooren JP
    Dermatology; 2002; 205(4):340-3. PubMed ID: 12444327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classic kaposi sarcoma: epidemiology and risk factors.
    Iscovich J; Boffetta P; Franceschi S; Azizi E; Sarid R
    Cancer; 2000 Feb; 88(3):500-17. PubMed ID: 10649240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.
    Patel R; Chang ALS
    Am J Clin Dermatol; 2019 Aug; 20(4):477-482. PubMed ID: 30737731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kaposi's sarcoma after repeated surgical procedures in an immunocompetent patient: the lymphatic hypothesis.
    Kostaki M; Pham XC; Toutous-Trellu L; Piguet V; Kaya G; Fasel JH; Stimec BV; Becker M; Salomon D
    Dermatology; 2010; 221(4):313-6. PubMed ID: 21051867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drug targets in Kaposi sarcoma.
    Sullivan RJ; Pantanowitz L
    Expert Opin Ther Targets; 2010 Dec; 14(12):1355-66. PubMed ID: 21043836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
    George S; Miao D; Demetri GD; Adeegbe D; Rodig SJ; Shukla S; Lipschitz M; Amin-Mansour A; Raut CP; Carter SL; Hammerman P; Freeman GJ; Wu CJ; Ott PA; Wong KK; Van Allen EM
    Immunity; 2017 Feb; 46(2):197-204. PubMed ID: 28228279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classic Kaposi's sarcoma associated with human herpesvirus 8 infection in a 13-year-old male: a case report.
    Landau HJ; Poiesz BJ; Dube S; Bogart JA; Weiner LB; Souid AK
    Clin Cancer Res; 2001 Aug; 7(8):2263-8. PubMed ID: 11489800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma.
    Kerr DA; Busarla SVP; Gimbel DC; Sohani AR; Nazarian RM
    Hum Pathol; 2017 Jul; 65():157-165. PubMed ID: 28506734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.